Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Outline of Final Research Achievements |
MWCL-1 was established as LPL cell line. MWCL-1 cells were classified into three subpopulations using a flow cytometer with anti-CD20 and anti-CD138 antibodies: CD20-CD138-, CD20+CD138-, and CD20+CD138+. When cultured, CD20-CD138- cells yielded all three subpopulations. Compared to the other subpopulations, CD20-CD138- cells possessed the efficient ROS expelling and in vitro colony formation activities, and were resistant to apoptosis. These results suggested that CD20-CD138- cells might be a candidate for tumor-initiating cells in LPL. Low oxygen culture of MWCL-1 induced the production of CD20-CD138- cells, and this result suggested that hypoxia was an advantageous microenvironment for CD20-CD138- cells. CXCR7 mRNA/protein expression was the highest in CD20-CD138- cells. When CXCL12, a ligand of CXCR7, was added, the proportion of CD20-CD138- cells significantly increased. CXCL12-CXCR7 signaling might exert a great influence on CD20-CD138- cells.
|